Details of the Drug Combination

General Information of Drug Combination (ID: DCSPR9B)

Drug Combination Name

Amonafide Vinflunine

Indication

Disease Entry	Status	REF
Non-small cell lung carcinoma	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Vinflunine DMTJAEP

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HOP-92

Zero Interaction Potency (ZIP) Score: 1.66

Bliss Independence Score: 2.37

Loewe Additivity Score: 5.17

LHighest Single Agent (HSA) Score: 6.09

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DC5U0PX	HCT-15	Investigative	[1]
Adult acute myeloid leukemia	DCNFACN	HL-60(TB)	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCVMZH2	MOLT-4	Investigative	[1]
Anaplastic large cell lymphoma	DC0YH00	SR	Investigative	[1]
Astrocytoma	DC22S8F	U251	Investigative	[1]
Large cell lung carcinoma	DCB9O8K	NCI-H460	Investigative	[1]
Carcinoma	DCRE1YA	MCF7	Investigative	[4]
Invasive ductal carcinoma	DCIG1BM	HS 578T	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.